<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Edgy</title>
	<atom:link href="http://www.tapanray.in/tag/edgy/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>India-like New Broader Compulsory Licensing Provisions in China Could Make the Global Pharma Players Edgy</title>
		<link>http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy</link>
		<comments>http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/#comments</comments>
		<pubDate>Mon, 18 Jun 2012 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Broader]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[could]]></category>
		<category><![CDATA[Edgy]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[like]]></category>
		<category><![CDATA[Make]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Provisions]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=79</guid>
		<description><![CDATA[Quite close on the heel of grant of Compulsory License (CL) to Bayer AG’s expensive Kidney and Liver cancer drug Sorafenib to the domestic Indian manufacturer Natco by the Indian Patent Office, as provided in the Indian Patent Law, China &#8230; <a href="http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-like-new-broader-compulsory-licensing-provisions-in-china-could-make-the-global-pharma-players-edgy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
